<DOC>
	<DOC>NCT01029158</DOC>
	<brief_summary>RN1006 has been developed as a stabilized formulation of avotermin which, when dosed once in pre-clinical studies in animals, has shown comparable scar improvement efficacy to the standard twice-dosed Juvista formulation. The aim of this trial is to investigate the efficacy of RN1006 compared to Juvista in a human volunteer model</brief_summary>
	<brief_title>A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo</brief_title>
	<detailed_description />
	<criteria>Males and females aged 1885 years who have given written informed consent Subjects with a body mass index within range 1835 kg/m2 Subjects with clinically acceptable results for the laboratory tests specified in the trial protocol Female subjects using a highly effective method (S) of contraception Subjects who have a history of keloid scarring, surgery within one year of the first dosing area Subjects who have current scars, tattoos, birthmarks, mole within 3 cm of the area to be excised Subjects with any clinically significant medical condition or history of any condition which may impair wound healing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Healthy volunteers</keyword>
	<keyword>Comparison of two formulations</keyword>
	<keyword>Improvement of scar appearance</keyword>
</DOC>